Ren J, Esnouf R, Hopkins A, Ross C, Jones Y, Stammers D, Stuart D
Laboratory of Molecular Biophysics, Oxford, UK.
Structure. 1995 Sep 15;3(9):915-26. doi: 10.1016/S0969-2126(01)00226-X.
HIV reverse transcriptase (RT) is a key target of anti-AIDS therapies. Structural studies of HIV-1 RT, unliganded and complexed with different non-nucleoside inhibitors (NNIs), have pointed to a common mode of binding and inactivation through distortion of the polymerase catalytic site by NNIs containing two hinged rings. The mode of binding of the TIBO family of inhibitors is of interest because these compounds do not fit the two-hinged-ring model.
The structure of HIV-1 RT complexed with 9-chloro-TIBO (R82913) has been determined at 2.6 A resolution. As reported for the lower resolution analysis of another TIBO compound, this inhibitor binds at the same site as other NNIs, but our higher resolution study reveals the Cl-TIBO is distorted from the conformation seen in crystals of the inhibitor alone. This allows Cl-TIBO to mimic the binding of NNIs containing two hinged rings. Inhibitor-protein interactions are again predominantly hydrophobic and the protein conformation corresponds to that seen in complexes with other tight-binding NNIs.
Although Cl-TIBO is chemically very different from other NNIs, it achieves remarkable spatial equivalence and shape complementarity with other NNIs on binding to RT. Comparison of the different RT-NNI complexes suggests modifications to the TIBO group of inhibitors which might enhance their binding and hence, potentially, their therapeutic efficacy.
HIV逆转录酶(RT)是抗艾滋病疗法的关键靶点。对未结合配体以及与不同非核苷抑制剂(NNIs)形成复合物的HIV-1 RT进行的结构研究表明,通过含有两个铰链环的NNIs使聚合酶催化位点发生扭曲,存在一种共同的结合和失活模式。TIBO家族抑制剂的结合模式备受关注,因为这些化合物不符合双铰链环模型。
已确定HIV-1 RT与9-氯-TIBO(R82913)形成复合物的结构,分辨率为2.6埃。正如对另一种TIBO化合物的低分辨率分析所报道的那样,该抑制剂与其他NNIs结合在同一位置,但我们更高分辨率的研究表明,Cl-TIBO与单独抑制剂晶体中所见的构象不同。这使得Cl-TIBO能够模拟含有两个铰链环的NNIs的结合。抑制剂与蛋白质的相互作用再次主要是疏水性的,并且蛋白质构象与在与其他紧密结合的NNIs形成的复合物中所见的构象一致。
尽管Cl-TIBO在化学上与其他NNIs有很大不同,但它在与RT结合时与其他NNIs实现了显著的空间等效性和形状互补性。对不同RT-NNI复合物的比较表明,对TIBO类抑制剂进行修饰可能会增强其结合能力,从而潜在地提高其治疗效果。